Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial

The Lancet Oncology
Birte FriedrichsNorbert Schmitz

Abstract

Most allogeneic haematopoietic stem cell transplants now use peripheral blood progenitor cell transplantation (PBPCT) instead of bone-marrow transplantation (BMT). Long-term data on outcome and late effects of PBPCT compared with BMT are scarce. Here we present long-term data from a randomised study comparing PBPCT with BMT. Between February, 1995, and September, 1999, 329 patients with leukaemia received either PBPCT (n=163) or BMT (n=166) from HLA-identical sibling donors after central randomisation accounting for stratification criteria. Follow-up data were collected via questionnaires from 87% (176 of 202; 84 PBPCT, 92 BMT) patients who survived for more than 3 years (median of 9.3 years) after transplantation. Efficacy analyses included all patients who received treatment. This study is registered with ClinicalTrials.gov, number NCT01020175. 10-year overall survival was 49.1% for patients who underwent PBPCT and 56.5% for patients who underwent BMT (HR 0.83, 95% CI 0.60-1.15; p=0.27). Leukaemia-free survival was 28.3% with BMT versus 13.0% with PBPCT (0.61, CI 0.32-1.16; p=0.12) for acute lymphoblastic leukaemia; 62.3% with BMT versus 47.1% with PBPCT for acute myeloid leukaemia (0.67, 0.39-1.16; p=0.16); and 40.2% with BM...Continue Reading

References

Jul 20, 2002·Blood·Norbert SchmitzUNKNOWN European Group for Blood and Marrow Transplantation
Oct 18, 2002·Blood·Mohamad MohtyUNKNOWN Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)
Jan 4, 2003·Blood·Gérard SociéUNKNOWN Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael G KiehlOlle Ringden
Jul 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN Stem Cell Trialists' Collaborative Group
Dec 18, 2007·Bone Marrow Transplantation·A GratwohlUNKNOWN European Group for Blood and Marrow Transplantation EBMT (JACIE)

❮ Previous
Next ❯

Citations

May 15, 2010·International Journal of Hematology·Yasushi IshidaKeizo Horibe
Nov 26, 2010·The New England Journal of Medicine·John H Kersey
Oct 19, 2012·The New England Journal of Medicine·Claudio AnasettiUNKNOWN Blood and Marrow Transplant Clinical Trials Network
Dec 19, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T H TerweyR Arnold
Dec 22, 2011·Current Opinion in Oncology·William I Bensinger
Feb 2, 2013·Blood·Roland MeiselUNKNOWN German/Austrian Pediatric Registry for Stem Cell Transplantation
Jun 29, 2012·The International Journal of Biostatistics·Dorota M Dabrowska
Feb 9, 2012·Haematologica·Andrea BacigalupoUNKNOWN Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation (WPSAA-EBMT)
Oct 1, 2013·Bone Marrow Transplantation·Y KoderaUNKNOWN European Blood and Marrow Transplant Group
Jun 29, 2016·Romanian Journal of Internal Medicine = Revue Roumaine De Médecine Interne·R-G Mihăilă
Oct 18, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Seitaro TerakuraUNKNOWN Japan Society for Hematopoietic Cell Transplantation
Oct 17, 2012·Blood Reviews·Ibraheem H Motabi, John F DiPersio
Aug 4, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jiro InagakiJun Okamura
Feb 11, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claire M VajdicUNKNOWN CAST study investigators
Apr 24, 2012·Journal of Internal Medicine·O RingdénUNKNOWN Acute Leukaemia Working Party of European Group for Blood and Marrow Transplantation (EBMT)
Sep 1, 2015·Methods : a Companion to Methods in Enzymology·Christopher D PoradaGraça Almeida-Porada
May 6, 2011·CA: a Cancer Journal for Clinicians·Judith A Paice, Betty Ferrell
Mar 23, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Yoshihiro InamotoPaul J Martin
Nov 24, 2011·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Hartmut BertzJürgen Finke
Aug 6, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Eneida R NemecekH Joachim Deeg
Jun 21, 2016·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Aleksandr Lazaryan
Jul 29, 2016·Der Urologe. Ausg. A·L-M Krabbe, S Schmidt
Jul 28, 2016·Bone Marrow Transplantation·M SladeR Romee
Dec 24, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary EapenRichard E Champlin
May 7, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A GlareKaren L Syrjala
Sep 27, 2014·World Journal of Stem Cells·Michael J RicciRonan S Foley
Sep 26, 2015·The Cochrane Database of Systematic Reviews·Angela G E M de BoerJos H Verbeek
Apr 22, 2014·The Cochrane Database of Systematic Reviews·Udo HoltickMichael von Bergwelt-Baildon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.